febuxostat tablets 10mg "dsep"[gout, hyperuricemia] (フェブキソスタット錠10mg「dsep」[痛風・高尿酸血症])
daiichi sankyo espha co., ltd. - febuxostat - white to light yellow tablet, diameter: approx. 7 mm, thickness: approx. 3 mm
febuxostat tablets 10mg "nipro"[for hyperuricemia associated with cancer chemotherapy] (フェブキソスタット錠10mg「ニプロ」[がん化学療法に伴う高尿酸血症])
nipro corporation - febuxostat - white to faint yellow tablet, diameter : 7.1 mm, thickness : 3.2 mm
ipratropium bromide/salbutamol neutec 0.5/2.5 mg per 2.5 ml nebuliser solution
neutec inhaler ireland limited - ipratropium bromide monohydrate; salbutamol sulfate - nebuliser solution - salbutamol and ipratropium bromide
uloric- febuxostat tablet
rebel distributors corp - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 80 mg - uloric® is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline [see drug interactions (7)] . pregnancy category c : there are no adequate and well-controlled studies in pregnant women. uloric should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. febuxostat was not teratogenic in rats and rabbits at oral doses up to 48 mg per kg (40 and 51 times the human plasma exposure at 80 mg per day for equal body surface area, respectively) during organogenesis. however, increased neonatal mortality and a reduction in the neonatal body weight gain were observed when pregnant rats were treated with oral doses up to 48 mg per kg (40 times the human plasma exposure at 80 mg per day) during organogenesis and through lactation period. febuxos
febuxostat od tablet 20mg"meiji"[for hyperuricemia associated with cancer chemotherapy] (フェブキソスタットod錠20mg「明治」[がん化学療法に伴う高尿酸血症])
meiji seika pharma co., ltd. - febuxostat - white to faint yellow tablet with split line, diameter: 7.0 mm, thickness: 3.0 mm
febuxostat od tablet 20mg"meiji"[for hyperuricemia associated with cancer chemotherapy] (フェブキソスタットod錠20mg「明治」[がん化学療法に伴う高尿酸血症])
me pharma co., ltd. - febuxostat - white to faint yellow tablet with split line, diameter: 7.0 mm, thickness: 3.0 mm
febuxostat od tablet 20mg"meiji"[gout, hyperuricemia] (フェブキソスタットod錠20mg「明治」[痛風・高尿酸血症])
me pharma co., ltd. - febuxostat - white to faint yellow tablet with split line, diameter: 7.0 mm, thickness: 3.0 mm
febuxostat od tablet 20mg"meiji"[gout, hyperuricemia] (フェブキソスタットod錠20mg「明治」[痛風・高尿酸血症])
meiji seika pharma co., ltd. - febuxostat - white to faint yellow tablet with split line, diameter: 7.0 mm, thickness: 3.0 mm
febuxostat od tablet 40mg"meiji"[for hyperuricemia associated with cancer chemotherapy] (フェブキソスタットod錠40mg「明治」[がん化学療法に伴う高尿酸血症])
meiji seika pharma co., ltd. - febuxostat - white to faint yellow tablet with split line, diameter: 9.0 mm, thickness: 3.8 mm
febuxostat od tablet 40mg"meiji"[for hyperuricemia associated with cancer chemotherapy] (フェブキソスタットod錠40mg「明治」[がん化学療法に伴う高尿酸血症])
me pharma co., ltd. - febuxostat - white to faint yellow tablet with split line, diameter: 9.0 mm, thickness: 3.8 mm